Skip to main content

Divita Charles III's Form 4 filing

Teladoc Health, Inc. (TDOC) · filed Mar 3, 2026

Accession no.
0001347535-26-000002
Filed
Mar 3, 2026
Trade date
Feb 27, 2022-Mar 2, 2026
Filing delay
1,465 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 4 derivative transactions. Open-market sales total $256.7K. It was filed 1465 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Divita Charles IIICIK 0001347535Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 27, 2022Common StockMOption exerciseAcquired+169,107––370,143Direct
Feb 27, 2026Common StockMOption exerciseAcquired+7,864––378,007Direct
Mar 2, 2026Common StockSSaleDisposed−50,145$5.12−$256,742.4327,862Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 27, 2026Common StockMOption exerciseDisposed−169,107$0.00$0338,215Direct
Feb 27, 2026Common StockAGrant or awardAcquired+23,591$0.00$023,591Direct
Feb 27, 2026Common StockMOption exerciseDisposed−7,864$0.00$015,727Direct
Mar 1, 2026Common StockAGrant or awardAcquired+692,041$0.00$0692,041Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)